Neuraxis, Inc. is a neuromodulation medical technology company that develops and commercializes percutaneous electrical nerve field stimulation (PENFS) therapies for disorders of gut-brain interaction in pediatric and adult populations. The company's flagship product, IB-Stim®, is an FDA-cleared device that delivers electrical stimulation to cranial nerve branches in the ear to treat functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia; it is deployed as a four-week treatment course with multiple device units and sold directly to children's hospitals, gastroenterologists, and other clinical settings. The company generates revenue through per-device sales and benefits from expanding insurance reimbursement and commercial coverage, while maintaining a competitive moat through patent protection, first-to-market positioning, and clinical evidence demonstrating efficacy and safety across hundreds of published patient cases.